Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Santhera will Publish its Interim Report for the First Half of 2021 on October 15, 2021

10/01/2021 | 01:00am EST

(MORE TO FOLLOW) Dow Jones Newswires

October 01, 2021 01:00 ET (05:00 GMT)

All news about SANTHERA PHARMACEUTICALS HOLDING AG
12/07Santhera to Host Investor Conference Call, Looking Ahead to 2022
AQ
12/06Santhera to File Rolling New Drug Application for Duchenne Treatment to US FDA in Early..
MT
12/06Santhera to Host Investor Conference Call — Looking Ahead to 2022
AQ
11/24Santhera's Board Calls Extraordinary General Meeting To Vote On Future Fundraisings
MT
11/24Santhera Provides Corporate Update and Calls Extraordinary General Meeting to Seek Appr..
DJ
11/24Santhera Pharmaceuticals Holding AG announced that it has received CHF 15 million in fu..
CI
11/23Santhera's Mid-Stage Trial For Duchenne Muscular Dystrophy Drug Shows Sustained Efficac..
MT
11/23Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completi..
AQ
11/17Santhera JV to Seek US FDA's New Drug Approval For Duchenne Muscular Dystrophy Treatmen..
MT
11/17Santhera and ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone in Duchen..
DJ
More news
Financials
Sales 2021 8,00 M 8,68 M 8,68 M
Net income 2021 -40,0 M -43,4 M -43,4 M
Net Debt 2021 - - -
P/E ratio 2021 -1,90x
Yield 2021 -
Capitalization 58,9 M 63,9 M 64,0 M
Capi. / Sales 2021 7,37x
Capi. / Sales 2022 1,11x
Nbr of Employees 86
Free-Float 82,0%
Chart SANTHERA PHARMACEUTICALS HOLDING AG
Duration : Period :
Santhera Pharmaceuticals Holding AG Technical Analysis Chart | SANN | CH0027148649 | MarketScreener
Technical analysis trends SANTHERA PHARMACEUTICALS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 1,40 CHF
Average target price 6,50 CHF
Spread / Average Target 363%
EPS Revisions
Managers and Directors
Dario Eklund Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Elmar J. Schnee Chairman
Martin Gertsch Vice Chairman
Philipp Gutzwiller Independent Director